| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
|
| ln Vitro |
The outcomes shown that HDP cells experienced the highest level of defense against ROS-induced cell damage following 10 μM troxerutin repair. After being exposed to H2O2, treatment with H2O2 alone decreased cell viability to 77.33±2.44%; however, shaping with 10 μM Troxerutin kept cell viability at 90.88±2.24% (P<0.05). When Troxerutin was used for shaping, the number of cells in the sub-G1 phase decreased, indicating cell death, at concentrations of 5 and 10 μM. 3.58±0.15 and 0.89±0.11% of normal and Troxerutin-treated cells, respectively, were 2'7'-dichlorofluorescein (DCF) positive (P<0.05), but ROS levels rose to 46.36± 2.33%2 in H2O-treated cells. Following treatment with H2O2, the DCF of cells devoid of Troxerutin declined dramatically by 19.92±1.95%, suggesting that Troxerutin inhibited the generation of ROS in HDP cells caused by H2O2 [1].
|
|---|---|
| ln Vivo |
Troxerutin treatment of mice on a high-fat diet (HFD) successfully lowers body weight and nutrition-related respiratory parameters. In HFD-treated mice, neck troxerutin can dramatically prevent liver damage, improve insulin signaling and poor stress, and lessen HFD-treated Troxerutin strongly suppresses the nuclear translocation of target genes and NF-κB p65. expression in the heart after an HFD. Troxerutin also prevents the myocardium fed with high-fat diet from being activated by the endoplasmic reticulum (ER) through the oligomerization domain (NOD). Compared to diabetes without treatment, troxerutin addresses oligomeric domains in the diabetes's media and intima. Compared to diabetes aorta histology that was not treated, there was a significant decrease in structural activation and smooth muscle cell effects in diabetic aortic tissue treated with troxerutin. Malonaldehyde (MDA) levels were considerably lower after 4 weeks of Troxerutin administration in diabetic arteries as compared to untreated diabetes (P<0.01) [3].
|
| References |
|
| Additional Infomation |
Troxerutin has been used in trials studying the treatment of Chronic Venous Insufficiency.
|
| Molecular Formula |
C33H42O19
|
|---|---|
| Molecular Weight |
742.68
|
| Exact Mass |
742.232
|
| CAS # |
7085-55-4
|
| PubChem CID |
5486699
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
1058.4±65.0 °C at 760 mmHg
|
| Melting Point |
168 - 176ºC
|
| Flash Point |
332.0±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.690
|
| LogP |
-0.32
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
52
|
| Complexity |
1170
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)OCCO)C5=CC(=C(C=C5)OCCO)OCCO)O)O)O)O)O)O
|
| InChi Key |
IYVFNTXFRYQLRP-VVSTWUKXSA-N
|
| InChi Code |
InChI=1S/C33H42O19/c1-14-23(38)26(41)28(43)32(49-14)48-13-21-24(39)27(42)29(44)33(51-21)52-31-25(40)22-17(37)11-16(45-7-4-34)12-20(22)50-30(31)15-2-3-18(46-8-5-35)19(10-15)47-9-6-36/h2-3,10-12,14,21,23-24,26-29,32-39,41-44H,4-9,13H2,1H3/t14-,21+,23-,24+,26+,27-,28+,29+,32+,33-/m0/s1
|
| Chemical Name |
2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one
|
| Synonyms |
Helveton; Flebil; Factor P-zyma
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~134.65 mM)
H2O : ≥ 50 mg/mL (~67.32 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 24 mg/mL (32.32 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3465 mL | 6.7324 mL | 13.4647 mL | |
| 5 mM | 0.2693 mL | 1.3465 mL | 2.6929 mL | |
| 10 mM | 0.1346 mL | 0.6732 mL | 1.3465 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
